Abstract
Hyaluronidases are enzymes that degrade hyaluronic acid, which constitutes an essential part of the extracellular matrix. Initially discovered in bacteria, hyaluronidases are known to be widely distributed in nature and have been found in many classes including insects, snakes, fish and mammals. In the human, six different hyaluronidases, HYAL1-4, HYAL-P1 and PH-20, have been identified. PH-20 exerts the strongest biologic activity, is found in high concentrations in the testicles and can be localized on the head and the acrosome of human spermatozoa. Today, animal-derived bovine or ovine testicular hyaluronidases as well as synthetic hyaluronidases are clinically applied as adjuncts to increase the bioavailability of drugs, for the therapy of extravasations, or for the management of complications associated with the aesthetic injection of hyaluronic acid-based fillers. Further applications in the fields of surgery, aesthetic medicine, immunology, oncology, and many others can be expected for years to come. Here, we give an overview over the molecular and cellular mode of action of hyaluronidase and the hyaluronic acid metabolism, as well as over current and potential future clinical applications of hyaluronidase.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- BEL:
-
Belotero®
- BTH:
-
Bovine testicular hyaluronidase
- CHO:
-
Chinese hamster ovary
- CPM:
-
Cohesive polydensified matrix
- DMSO:
-
Dimethylsulfoxide
- ECM:
-
Extracellular matrix
- EMV:
-
Emervel®
- FDA:
-
Food and Drug Administration
- GAG:
-
Glycosaminoglycan
- HA:
-
Hyaluronan
- HAS:
-
Hyaluronan synthase
- HYAL:
-
Hyaluronidase
- Ig:
-
Immunoglobulin
- IGSC:
-
Subcutaneous immunoglobulins
- IU:
-
International units
- JUV:
-
Juvederm®
- kDA:
-
Kilodalton
- l:
-
Liter
- LA:
-
Local anesthetic
- mAb:
-
Monoclonal antibody
- ml:
-
Milliliter
- μm:
-
Micrometer
- OTH:
-
Ovine testicular hyaluronidase
- PEGPH20:
-
PEGylated recombinant human hyaluronidase
- PG:
-
Proteoglycan
- RES:
-
Restylane®
- rHuPH20:
-
Recombinant human hyaluronidase
- S. aureus :
-
Staphylococcus aureus
References
Ahmed S, Ahmed OA (2004) Hyaluronidase revisited-a single injection technique for harvesting split thickness skin grafts under local anaesthesia. Br J Plast Surg 57:589–591
Albanell J, Baselga J (2000) Systemic therapy emergencies. Semin Oncol 27:347–361
Alberts DS, Dorr RT (1991) Case report: topical DMSO for mitomycin-C-induced skin ulceration. Oncol Nurs Forum 18:693–695
Allen CH, Etzwiler LS, Miller MK et al (2009) Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics 124:e858–e867
Aruffo A, Stamenkovic I, Melnick M et al (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303–1313
Atmuri V, Martin DC, Hemming R et al (2008) Hyaluronidase 3 (HYAL3) knockout mice do not display evidence of hyaluronan accumulation. Matrix Biol 27:653–660
Attenello NH, Maas CS (2015) Injectable fillers: review of material and properties. Facial Plast Surg 31:29–34
Ballin AC, Cazzaniga A, Brandt FS (2013) Long-term efficacy, safety and durability of Juvederm(R) XC. Clin Cosmet Investig Dermatol 6:183–189
Barsukov AK, Kozhevnikova OV, Khokhriakova AV (2003) Isolation and purification of bovine testicular hyaluronidase. Prikl Biokhim Mikrobiol 39:625–629
Beleznay K, Carruthers JD, Humphrey S et al (2015) Avoiding and treating blindness from fillers: a review of the world literature. Dermatol Surg 41:1097–1117
Bellin MF, Jakobsen JA, Tomassin I et al (2002) Contrast medium extravasation injury: guidelines for prevention and management. Eur Radiol 12:2807–2812
Belzunegui T, Louis CJ, Torrededia L et al (2011) Extravasation of radiographic contrast material and compartment syndrome in the hand: a case report. Scand J Trauma Resusc Emerg Med 19:9
Benditt EP, Schiller S, Matthews MB et al (1951) Evidence that hyaluronidase is not the factor in testicular extract causing increased vascular permeability. Proc Soc Exp Biol Med 77:643–646
Bertelli G (1995) Prevention and management of extravasation of cytotoxic drugs. Drug Saf 12:245–255
Bertelli G, Dini D, Forno GB et al (1994) Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J Cancer Res Clin Oncol 120:505–506
Bertelli G, Gozza A, Forno GB et al (1995) Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13:2851–2855
Bertelli G, Cafferata MA, Ardizzoni A et al (1997) Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 79:2266–2269
Bertolami CN, Donoff RB (1982) Identification, characterization, and partial purification of mammalian skin wound hyaluronidase. J Invest Dermatol 79:417–421
Bissell MJ, Hall HG, Parry G (1982) How does the extracellular matrix direct gene expression? J Theor Biol 99:31–68
Bohaumilitzky L, Huber AK, Stork EM et al (2017) A trickster in disguise: Hyaluronan’s ambivalent roles in the matrix. Front Oncol 7:242
Bookbinder LH, Hofer A, Haller MF et al (2006) A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114:230–241
Boulanger J, Ducharme A, Dufour A et al (2015) Management of the extravasation of anti-neoplastic agents. Support Care Cancer 23:1459–1471
Buhren BA, Schrumpf H, Hoff NP et al (2016) Hyaluronidase: from clinical applications to molecular and cellular mechanisms. Eur J Med Res 21:5
Buhren BA, Schrumpf H, Bolke E et al (2018) Standardized in vitro analysis of the degradability of hyaluronic acid fillers by hyaluronidase. Eur J Med Res 23:37
Buntrock H, Reuther T, Prager W et al (2013) Efficacy, safety, and patient satisfaction of a monophasic cohesive polydensified matrix versus a biphasic nonanimal stabilized hyaluronic acid filler after single injection in nasolabial folds. Dermatol Surg 39:1097–1105
Carne E, Ponsford M, El-Shanawany T et al (2016) Five years of self-administered hyaluronidase facilitated subcutaneous immunoglobulin (fSCIg) home therapy in a patient with primary immunodeficiency. J Clin Pathol 69:87–88
Cochran ST, Bomyea K, Kahn M (2002) Treatment of iodinated contrast material extravasation with hyaluronidase. Acad Radiol 9(Suppl 2):S544–S546
Connolly AA, Meyer LC, Tate JJ (1994) Local anaesthetic agents in surgery for ingrown toenail. Br J Surg 81:425–426
Connolly S, Korzemba H, Harb G et al (2011) Techniques for hyaluronidase-facilitated subcutaneous fluid administration with recombinant human hyaluronidase: the increased flow utilizing subcutaneously enabled administration technique (INFUSE AT) study. J Infus Nurs 34:300–307
Courtiss EH, Ransil BJ, Russo J (1995) The effects of hyaluronidase on local anesthesia: a prospective, randomized, controlled, double-blind study. Plast Reconstr Surg 95:876–883
Cowman MK (2017) Hyaluronan and hyaluronan fragments. Adv Carbohydr Chem Biochem 74:1–59
Crawford M, Kerr WJ (1994) The effect of hyaluronidase on peribulbar block. Anaesthesia 49:907–908
Csoka TB, Frost GI, Stern R (1997) Hyaluronidases in tissue invasion. Invasion Metastasis 17:297–311
Dai G, Freudenberger T, Zipper P et al (2007) Chronic ultraviolet B irradiation causes loss of hyaluronic acid from mouse dermis because of down-regulation of hyaluronic acid synthases. Am J Pathol 171:1451–1461
Dayan SH, Bassichis BA (2008) Facial dermal fillers: selection of appropriate products and techniques. Aesthet Surg J 28:335–347
De Boulle K, Glogau R, Kono T et al (2013) A review of the metabolism of 1,4-butanediol diglycidyl ether-crosslinked hyaluronic acid dermal fillers. Dermatol Surg 39:1758–1766
Delorenzi C (2013) Complications of injectable fillers, part I. Aesthet Surg J 33:561–575
Dempsey GA, Barrett PJ, Kirby J (1996) The effect of hyaluronidase on peribulbar block. Anaesthesia 51:515
Dempsey GA, Barrett PJ, Kirby IJ (1997) Hyaluronidase and peribulbar block. Br J Anaesth 78:671–674
Dieleman M, Bettink-Remeijer MW, Jansen J et al (2012) High incidence of adverse reactions to locoregional anaesthesia containing hyaluronidase after uneventful ophthalmic surgery. Acta Ophthalmol 90:e245–e246
Doellman D, Hadaway L, Bowe-Geddes LA et al (2009) Infiltration and extravasation: update on prevention and management. J Infus Nurs 32:203–211
Doherty GJ, Tempero M, Corrie PG (2018) HALO-109-301: a phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol 14:13–22
Dorr RT (1990) Antidotes to vesicant chemotherapy extravasations. Blood Rev 4:41–60
Dougherty L (2008) IV therapy: recognizing the differences between infiltration and extravasation. Br J Nurs 17:896. 898–901
Dubois A, Fehr M, Bochtler H et al (1996) Clinical course and management of paclitaxel extravasation. Oncol Rep 3:973–974
Dunagin WG (1982) Clinical toxicity of chemotherapeutic agents: dermatologic toxicity. Semin Oncol 9:14–22
Dunn AL, Heavner JE, Racz G et al (2010) Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management. Expert Opin Biol Ther 10:127–131
Duran-Reynals F (1942) TISSUE PERMEABILITY AND THE SPREADING FACTORS IN INFECTION: a contribution to the host: parasite problem. Bacteriol Rev 6:197–252
Edsman K, Nord LI, Ohrlund A et al (2012) Gel properties of hyaluronic acid dermal fillers. Dermatol Surg 38:1170–1179
Elam EA, Dorr RT, Lagel KE et al (1991) Cutaneous ulceration due to contrast extravasation. Experimental assessment of injury and potential antidotes. Investig Radiol 26:13–16
El-Saghir N, Otrock Z, Mufarrij A et al (2004) Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol 5:320–321
Fanning GL (2001) Hyaluronidase in ophthalmic anesthesia. Anesth Analg 92:560
Farr C, Menzel J, Seeberger J et al (1997) Clinical pharmacology and possible applications of hyaluronidase with reference to Hylase “Dessau”. Wien Med Wochenschr 147:347–355
Federle MP, Chang PJ, Confer S et al (1998) Frequency and effects of extravasation of ionic and nonionic CT contrast media during rapid bolus injection. Radiology 206:637–640
Flynn TC, Sarazin D, Bezzola A et al (2011) Comparative histology of intradermal implantation of mono and biphasic hyaluronic acid fillers. Dermatol Surg 37:637–643
Fox AN, Villanueva R, Miller JL (2017) Management of amiodarone extravasation with intradermal hyaluronidase. Am J Health Syst Pharm 74:1545–1548
Fraser JR, Laurent TC, Pertoft H et al (1981) Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J 200:415–424
Fraser JR, Laurent TC, Laurent UB (1997) Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 242:27–33
Fronza M, Caetano GF, Leite MN et al (2014) Hyaluronidase modulates inflammatory response and accelerates the cutaneous wound healing. PLoS One 9:e112297
Frost GI (2007) Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 4:427–440
Garg SK, Buse JB, Skyler JS et al (2014) Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. Diabetes Obes Metab 16:1065–1069
Garvin JH Jr, Chipman DM (1974) Subunit structure of testicular hyaluronidase. FEBS Lett 39:157–159
Glogau RG (1997) Physiologic and structural changes associated with aging skin. Dermatol Clin 15:555–559
Goolsby TV, Lombardo FA (2006) Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol 33:139–143
Guedan S, Rojas JJ, Gros A et al (2010) Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 18:1275–1283
Gul A, Can E, Niyaz L et al (2015) Hyaluronidase in ophthalmic evisceration surgery. Trop Dr 45:100–104
Hamizi S, Freyer G, Bakrin N et al (2013) Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer. Onco Targets Ther 6:89–94
Harb G, Lebel F, Battikha J et al (2010) Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin 26:279–288
Harman D (1992) Role of free radicals in aging and disease. Ann N Y Acad Sci 673:126–141
Hascall V, Esko JD (2015) Hyaluronan. In: Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M, Darvill AG, Kinoshita T, Packer NH, Prestegard JH, Schnaar RL, Seeberger PH (eds) Essentials of glycobiology. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
Henson PM (1971a) The immunologic release of constituents from neutrophil leukocytes. II. Mechanisms of release during phagocytosis, and adherence to nonphagocytosable surfaces. J Immunol 107:1547–1557
Henson PM (1971b) The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles. J Immunol 107:1535–1546
Herman IM, Castellot JJ Jr (1987) Regulation of vascular smooth muscle cell growth by endothelial-synthesized extracellular matrices. Arteriosclerosis 7:463–469
Hilton S, Schrumpf H, Buhren BA et al (2014) Hyaluronidase injection for the treatment of eyelid edema: a retrospective analysis of 20 patients. Eur J Med Res 19:30
Hirsch RJ, Brody HJ, Carruthers JD (2007a) Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid. J Cosmet Laser Ther 9:182–185
Hirsch RJ, Cohen JL, Carruthers JD (2007b) Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg 33:357–360
Hompesch M, Muchmore DB, Morrow L et al (2011) Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care 34:666–668
Hwang E, Song YS (2017) Quantitative correlation between hyaluronic acid filler and hyaluronidase. J Craniofac Surg 28:838–841
Hyde CE, Old RW (1999) Expression pattern of a novel hyaluronidase during Xenopus embryogenesis. Mech Dev 82:213–217
Jahn K, Homey B, Gerber PA (2014) Management of complications after aesthetic hyaluronic acid injections. Hautarzt 65:851–853
Jones D, Tezel A, Borrell M (2010) In vitro resistance to degradation of hyaluronic acid dermal fillers by ovine testicular hyaluronidase. Dermatol Surg 36:804–809
Juhasz MLW, Levin MK, Marmur ES (2017) The kinetics of reversible hyaluronic acid filler injection treated with hyaluronidase. Dermatol Surg 43:841–847
Juhlin L (1997) Hyaluronan in skin. J Intern Med 242:61–66
Kagan L, Mager DE (2013) Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos 41:248–255
Kassner E (2000) Evaluation and treatment of chemotherapy extravasation injuries. J Pediatr Oncol Nurs 17:135–148
Kenne L, Gohil S, Nilsson EM et al (2013) Modification and cross-linking parameters in hyaluronic acid hydrogels – definitions and analytical methods. Carbohydr Polym 91:410–418
Khandwala M, Ahmed S, Goel S et al (2008) The effect of hyaluronidase on ultrasound-measured dispersal of local anaesthetic following sub-Tenon injection. Eye (Lond) 22:1065–1068
Khorlin AY, Vikha IV, Milishnikov AN (1973) Subunit structure of testicular hyaluronidase. FEBS Lett 31:107–110
Kim DW, Yoon ES, Ji YH et al (2011) Vascular complications of hyaluronic acid fillers and the role of hyaluronidase in management. J Plast Reconstr Aesthet Surg 64:1590–1595
Kind LS, Roffler S (1961) Allergic reactions to hyaluronidase. Proc Soc Exp Biol Med 106:734–735
Kontis TC (2013) Contemporary review of injectable facial fillers. JAMA Facial Plast Surg 15:58–64
Kreil G (1995) Hyaluronidases – a group of neglected enzymes. Protein Sci 4:1666–1669
Kuppermann BD, Thomas EL, De Smet MD et al (2005) Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 140:573–584
Landau M (2015) Hyaluronidase caveats in treating filler complications. Dermatol Surg 41(Suppl 1):S347–S353
Landsman L, Mandy SH (1991) Adjuncts to scalp reduction surgery. Intraoperative tissue expanders and hyaluronidase. J Dermatol Surg Oncol 17:670–672
Langer SW, Sehested M, Jensen PB (2000) Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 6:3680–3686
Laurent TC, Fraser JR (1992) Hyaluronan. FASEB J 6:2397–2404
Lee A, Grummer SE, Kriegel D et al (2010) Hyaluronidase. Dermatol Surg 36:1071–1077
Lewis-Smith PA (1986) Adjunctive use of hyaluronidase in local anaesthesia. Br J Plast Surg 39:554–558
Lindley-Jones MF (2000) Topical anaesthesia for phacoemulsification surgery. Clin Exp Ophthalmol 28:287–289
Lokeshwar VB, Selzer MG (2008) Hyalurondiase: both a tumor promoter and suppressor. Semin Cancer Biol 18:281–287
Lokeshwar VB, Rubinowicz D, Schroeder GL et al (2001) Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 276:11922–11932
Lorenc ZP, Fagien S, Flynn TC et al (2013) Review of key Belotero Balance safety and efficacy trials. Plast Reconstr Surg 132:33S–40S
Lv SH, Rong SF, Cai BG et al (2015) Property and current clinical applications of mammal hyaluronidase. Eur Rev Med Pharmacol Sci 19:3968–3976
Maccara ME (1983) Extravasation: a hazard of intravenous therapy. Drug Intell Clin Pharm 17:713–717
Martin-Deleon PA (2011) Germ-cell hyaluronidases: their roles in sperm function. Int J Androl 34:e306–e318
Martinez-Quintanilla J, He D, Wakimoto H et al (2015) Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol Ther 23:108–118
Mcclean D (1941) Studies on diffusing factors: the hyaluronidase activity of testicular extracts, bacterial culture filtrates and other agents that increase tissue permeability. Biochem J 35:159–183
Menzel EJ, Farr C (1998) Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Cancer Lett 131:3–11
Menzinger S, Kaya A, Saurat JH et al (2016) Injected hyaluronidase reduces the volume of exogenous hyaluronate fillers in mice and results in clinical improvement in a patient with pretibial myxedema. Dermatopathology (Basel) 3:61–67
Meyer AW (1937) The hunters in embryology: part III. Cal West Med 46:38–40
Meyer K (1947) The biological significance of hyaluronic acid and hyaluronidase. Physiol Rev 27:335–359
Meyer LJ, Stern R (1994) Age-dependent changes of hyaluronan in human skin. J Invest Dermatol 102:385–389
Montgomery LA, Budreau GK (1996) Implementing a clinical practice guideline to improve pediatric intravenous infiltration outcomes. AACN Clin Issues 7:411–424
Morcos PN, Zhang X, Mcintyre C et al (2013) Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. Int J Clin Pharmacol Ther 51:537–548
Muchmore DB, Vaughn DE (2010) Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J Diabetes Sci Technol 4:419–428
Myung Y, Yim S, Jeong JH et al (2017) The classification and prognosis of periocular complications related to blindness following cosmetic filler injection. Plast Reconstr Surg 140:61–64
Narayanan R, Kuppermann BD (2009) Hyaluronidase for pharmacologic vitreolysis. Dev Ophthalmol 44:20–25
Narins RS, Bowman PH (2005) Injectable skin fillers. Clin Plast Surg 32:151–162
Narins RS, Coleman WP 3rd, Donofrio LM et al (2010) Improvement in nasolabial folds with a hyaluronic acid filler using a cohesive polydensified matrix technology: results from an 18-month open-label extension trial. Dermatol Surg 36(Suppl 3):1800–1808
Narins RS, Brandt FS, Dayan SH et al (2011) Persistence of nasolabial fold correction with a hyaluronic acid dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg 37:644–650
Olver IN, Aisner J, Hament A et al (1988) A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6:1732–1735
Ozturk CN, Li Y, Tung R et al (2013) Complications following injection of soft-tissue fillers. Aesthet Surg J 33:862–877
Papakonstantinou E, Roth M, Karakiulakis G (2012) Hyaluronic acid: a key molecule in skin aging. Dermatoendocrinology 4:253–258
Perrault M, Housset E (1952) Hyaluronidase and its therapeutic applications. Therapie 7:196–206
Pirrello RD, Ting Chen C, Thomas SH (2007) Initial experiences with subcutaneous recombinant human hyaluronidase. J Palliat Med 10:861–864
Rao V, Chi S, Woodward J (2014) Reversing facial fillers: interactions between hyaluronidase and commercially available hyaluronic-acid based fillers. J Drugs Dermatol 13:1053–1056
Rees MD, Hawkins CL, Davies MJ (2004) Hypochlorite and superoxide radicals can act synergistically to induce fragmentation of hyaluronan and chondroitin sulphates. Biochem J 381:175–184
Remy M, Pinter F, Nentwich MM et al (2008) Efficacy and safety of hyaluronidase 75 IU as an adjuvant to mepivacaine for retrobulbar anesthesia in cataract surgery. J Cataract Refract Surg 34:1966–1969
Reynolds PM, Maclaren R, Mueller SW et al (2014) Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy 34:617–632
Ridenour S, Reader A, Beck M et al (2001) Anesthetic efficacy of a combination of hyaluronidase and lidocaine with epinephrine in inferior alveolar nerve blocks. Anesth Prog 48:9–15
Romagnoli M, Belmontesi M (2008) Hyaluronic acid-based fillers: theory and practice. Clin Dermatol 26:123–159
Rowlett J (2012) Extravasation of contrast media managed with recombinant human hyaluronidase. Am J Emerg Med 30:2102 e1–2102 e3
Sall I, Ferard G (2007) Comparison of the sensitivity of 11 crosslinked hyaluronic acid gels to bovine testis hyaluronidase. Polym Degrad Stab 92:915–919
Sbitany H, Koltz PF, Mays C et al (2010) CT contrast extravasation in the upper extremity: strategies for management. Int J Surg 8:384–386
Schonenberg H (1952) Therapeutic use of hyaluronidase in pediatrics. Kinderarztl Prax 20:223–228
Schoog M (1951) Therapeutic use of hyaluronidase. Dermatol Wochenschr 124:1033–1037
Schrijvers DL (2003) Extravasation: a dreaded complication of chemotherapy. Ann Oncol 14(Suppl 3):iii26–iii30
Schummer W, Schummer C, Muller A et al (2003) Extravasation: a rare complication of central venous cannulation? Case report of an imminent erosion of the common carotid artery. Anaesthesist 52:711–717
Schwartz DM, Shuster S, Jumper MD et al (1996) Human vitreous hyaluronidase: isolation and characterization. Curr Eye Res 15:1156–1162
Schwartzman J (1951) Hyaluronidase in pediatrics. N Y State J Med 51:215–221
Selek H, Ozer H, Aygencel G et al (2007) Compartment syndrome in the hand due to extravasation of contrast material. Arch Orthop Trauma Surg 127:425–427
Shpilberg O, Jackisch C (2013) Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer 109:1556–1561
Silverstein SM, Greenbaum S, Stern R (2012) Hyaluronidase in ophthalmology. J Appl Res 12(1):1–13
Smith KJ, Skelton HG, Turiansky G et al (1997) Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi’s sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol 36:239–242
Soldi A (1951) Hyaluronidase and its therapeutic applications. Farmacol Sci Tec 6:765–791
Soltes L, Mendichi R, Kogan G et al (2006) Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules 7:659–668
Spandorfer PR, Mace SE, Okada PJ et al (2012) A randomized clinical trial of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in mild to moderately dehydrated children in the emergency department. Clin Ther 34:2232–2245
Speth F, Haas JP, Hinze CH (2016) Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. Pediatr Rheumatol Online J 14:52
Stanford BL, Hardwicke F (2003) A review of clinical experience with paclitaxel extravasations. Support Care Cancer 11:270–277
Stebliuk PN (1972) Combined effect of hyaluronidase, ribonuclease and antibiotics on pathogenous Staphylococci. Vrach Delo 4:151
Stern R (2008) Hyaluronidases in cancer biology. Semin Cancer Biol 18:275–280
Stern R, Asari AA, Sugahara KN (2006) Hyaluronan fragments: an information-rich system. Eur J Cell Biol 85:699–715
Stocks D, Sundaram H, Michaels J et al (2011) Rheological evaluation of the physical properties of hyaluronic acid dermal fillers. J Drugs Dermatol 10:974–980
Sundaram H, Voigts B, Beer K et al (2010) Comparison of the rheological properties of viscosity and elasticity in two categories of soft tissue fillers: calcium hydroxylapatite and hyaluronic acid. Dermatol Surg 36(Suppl 3):1859–1865
Tammi R, Ripellino JA, Margolis RU et al (1988) Localization of epidermal hyaluronic acid using the hyaluronate binding region of cartilage proteoglycan as a specific probe. J Invest Dermatol 90:412–414
Tezel A, Fredrickson GH (2008) The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther 10:35–42
Thomas JR, Wallace MS, Yocum RC et al (2009) The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manag 38:663–672
Thorpe JN (1951) Procaine with hyaluronidase as local anesthetic. Lancet 1:210–211
Tran C, Carraux P, Micheels P et al (2014) In vivo bio-integration of three hyaluronic acid fillers in human skin: a histological study. Dermatology 228:47–54
Valko M, Leibfritz D, Moncol J et al (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44–84
Vaughn DE, Yocum RC, Muchmore DB et al (2009) Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 11:345–352
Volpi N, Schiller J, Stern R et al (2009) Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem 16:1718–1745
Wang CL, Cohan RH, Ellis JH et al (2007) Frequency, management, and outcome of extravasation of nonionic iodinated contrast medium in 69,657 intravenous injections. Radiology 243:80–87
Wang M, Li W, Zhang Y et al (2017) Comparison of intra-arterial and subcutaneous testicular hyaluronidase injection treatments and the vascular complications of hyaluronic acid filler. Dermatol Surg 43:246–254
Warnery, Dumon G, Brin et al (1954) Antibiotics and hyaluronidase combined in aerosols in the treatment of lesions of pulmonary tuberculosis; 20 months’ trial. Rev Tuberc 18:37–45
Wasserman RL (2017) Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy 9:1035–1050
Wasserman RL, Melamed I, Stein MR et al (2012) Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 130:951–7 e11
Wasserman RL, Melamed I, Kobrynski L et al (2016) Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. Immunotherapy 8:1175–1186
Weigel PH (2015) Hyaluronan synthase: the mechanism of initiation at the reducing end and a pendulum model for polysaccharide translocation to the cell exterior. Int J Cell Biol 2015:367579
Weller K, Maurer M, Fridman M et al (2017) Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy Asthma Proc 38:143–151
Wiegand R, Brown J (2010) Hyaluronidase for the management of dextrose extravasation. Am J Emerg Med 28:257 e1–257 e2
Wohlrab J, Finke R, Franke WG et al (2012a) Clinical trial for safety evaluation of hyaluronidase as diffusion enhancing adjuvant for infiltration analgesia of skin with lidocaine. Dermatol Surg 38:91–96
Wohlrab J, Finke R, Franke WG et al (2012b) Efficacy study of hyaluronidase as a diffusion promoter for lidocaine in infiltration analgesia of skin. Plast Reconstr Surg 129:771e–772e
Wohlrab J, Wohlrab D, Wohlrab L et al (2014) Use of hyaluronidase for pharmacokinetic increase in bioavailability of intracutaneously applied substances. Skin Pharmacol Physiol 27:276–282
Yocum RC, Kennard D, Heiner LS (2007) Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs 30:293–299
Yui N, Nihira J, Okano T et al (1993) Regulated release of drug microspheres from inflammation responsive degradable matrices of crosslinked hyaluronic acid. J Control Release 25:133–143
Zahl K, Jordan A, Mcgroarty J et al (1991) Peribulbar anesthesia. Effect of bicarbonate on mixtures of lidocaine, bupivacaine, and hyaluronidase with or without epinephrine. Ophthalmology 98:239–242
Zaneveld LJ, Polakoski KL, Schumacher GF (1973) Properties of acrosomal hyaluronidase from bull spermatozoa. Evidence for its similarity to testicular hyaluronidase. J Biol Chem 248:564–570
Zaoli G (1958) Hyaluronidase-antibiotic association in the treatment of acute otitis media of the infant & child. Minerva Otorinolaringol 8:354–358
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Weber, G.C., Buhren, B.A., Schrumpf, H., Wohlrab, J., Gerber, P.A. (2019). Clinical Applications of Hyaluronidase. In: Labrou, N. (eds) Therapeutic Enzymes: Function and Clinical Implications. Advances in Experimental Medicine and Biology, vol 1148. Springer, Singapore. https://doi.org/10.1007/978-981-13-7709-9_12
Download citation
DOI: https://doi.org/10.1007/978-981-13-7709-9_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-7708-2
Online ISBN: 978-981-13-7709-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)